ReviewClinics (Sao Paulo, Brazil)2018
Carcinoid syndrome: update on the pathophysiology and treatment.
Review in Clinics (Sao Paulo, Brazil), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators.Endocrine reviews · 2024Pooled it
- TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.The oncologist · 2019Trial
- Unusual paraneoplastic thrombocytosis in small bowel neuroendocrine tumor responding toJCEM case reports · 2026Article
- Primary Ovarian Neuroendocrine Neoplasm With Carcinoid Syndrome and Carcinoid Heart Disease.Ochsner journal · 2026Article
- Nonmetastatic Pulmonary Carcinoid Presenting With Carcinoid Syndrome Despite Negative 5-HIAA: A Case Report.Case reports in endocrinology · 2026Article
- From companion animals to patients: interspecies lessons in neuroendocrine oncology.Frontiers in veterinary science · 2026Review
- A Rare Case of Neuroendocrine Tumor Presenting as Isolated Scalp Swelling With Paroxysmal Symptoms.Cureus · 2025Article
- Article
- A case of carcinoid syndrome after CT guided lung biopsy of a neuroendocrine tumor.Radiology case reports · 2024Article
- Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.Current issues in molecular biology · 2024Review
- Carcinoid Heart Disease.Journal of the advanced practitioner in oncology · 2024Article
- Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Current oncology (Toronto, Ont.) · 2024Review
- Article
- The skin as a window to the gut: A case of carcinoid syndrome.Clinical case reports · 2024Article
- Nodular image in the appendix observed on ultrasound: endometriosis or neuroendocrine neoplasia?Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024Article
- Percutaneous transcatheter pulmonary and tricuspid valve replacements in a patient with carcinoid heart disease.European heart journal. Case reports · 2023Article
- NT-proBNP as a neuroendocrine tumor biomarker: beyond heart failure.Endocrine connections · 2023Article
- Carcinoid syndrome caused by a pulmonary carcinoid mimics intestinal manifestations of ulcerative colitis: A case report.World journal of gastroenterology · 2023Article
- Exploring the Link Between Pancreatic Neuroendocrine Tumors and Depression: A Case Study.Cureus · 2023Article
- Carcinoid Heart Disease: A Case Report and Literature Review.Arquivos brasileiros de cardiologia · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 30-40% of patients with well-differentiated neuroendocrine tumors present with carcinoid syndrome, which is a paraneoplastic syndrome associated with the secretion of several humoral factors. Carcinoid syndrome significantly and negatively affects patients' quality of life; increases costs compared with the costs of nonfunctioning neuroendocrine tumors; and results in changes in patients' lifestyle, such as diet, work, physical activity and social life. For several decades, patients with neuroendocrine tumors and carcinoid syndrome have been treated with somatostatin analogues as the first-line treatment. While these agents provide significant relief from carcinoid syndrome symptoms, there is inevitable clinical progression, and new therapeutic interventions are needed. More than 40 substances have been identified as being potentially related to carcinoid syndrome; however, their individual contributions in triggering different carcinoid symptoms or complications, such as carcinoid heart disease, remain unclear. These substances include serotonin (5-HT), which appears to be the primary marker associated with the syndrome, as well as histamine, kallikrein, prostaglandins, and tachykinins. Given the complexity involving the origin, diagnosis and management of patients with carcinoid syndrome, we have undertaken a comprehensive review to update information about the pathophysiology, diagnostic tools and treatment sequence of this syndrome, which currently comprises a multidisciplinary approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.